Apellis Pharmace Stock Price, News & Analysis

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) is a commercial-stage, global biopharmaceutical company focused on the discovery, development, and commercialization of therapies based on complement science. According to the company, it is advancing medicines that target C3, the central protein in the complement cascade, a key component of the immune system. Apellis has brought forward a new class of complement medicine and has C3-targeting therapies approved to treat multiple serious diseases.

Apellis is classified in Pharmaceutical Preparation Manufacturing within the Manufacturing sector and its common stock trades on the Nasdaq Global Select Market under the symbol APLS. The company describes itself as global, with a focus on developing therapies for some of the most challenging diseases patients face, particularly where excessive activation of the complement cascade plays a central role.

Core focus on C3 and complement science

Apellis concentrates on inhibition and regulation of C3 in the complement system. By targeting C3, its medicines are designed to control excessive complement activation, which the company states can drive the onset and progression of serious diseases. This scientific focus underpins both its ophthalmology and rare disease franchises and is reflected in its approved products and clinical programs.

The company highlights that it ushered in the first new class of complement medicine in many years and that it continues to explore the potential of targeting C3 across additional diseases. Its work spans approved therapies, late-stage clinical trials, and pre-clinical research programs that build on its complement expertise.

Approved medicines and key therapeutic areas

Apellis has two branded C3-targeting medicines based on pegcetacoplan:

• SYFOVRE (pegcetacoplan injection) – described by Apellis as the first-ever approved therapy for geographic atrophy (GA) secondary to age-related macular degeneration. SYFOVRE is approved in the United States for GA and, in certain disclosures, is also noted as approved in Australia. By targeting C3, SYFOVRE is designed to provide comprehensive control of the complement cascade in the eye.
• EMPAVELI / Aspaveli (pegcetacoplan) – a targeted C3 therapy designed to regulate excessive activation of the complement cascade systemically. EMPAVELI is the first treatment approved in the United States for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC‑MPGN) in patients 12 years of age and older to reduce proteinuria. EMPAVELI/Aspaveli is also approved for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) in the United States, European Union, and other countries.

Across these indications, Apellis emphasizes that its therapies address serious, often rare diseases with high unmet medical need, including GA, a leading cause of blindness, and severe kidney diseases such as C3G and primary IC‑MPGN.

Ophthalmology franchise: geographic atrophy

Within ophthalmology, Apellis is focused on transforming the treatment of geographic atrophy secondary to age-related macular degeneration. SYFOVRE is positioned by the company as the leading treatment in GA, with disclosures noting that it remains the market leader with an estimated total market share of approximately 60% and a substantial share of new patient starts in GA.

Apellis reports extensive clinical and real-world experience with SYFOVRE, including long-term data from the GALE extension study following five years of continuous treatment. A post hoc analysis of GALE showed that both every‑other‑month and monthly SYFOVRE delayed GA lesion growth by approximately 1.5 years in patients with nonsubfoveal GA when compared to sham or projected sham. The company notes that these five‑year results support the impact of targeting C3 with SYFOVRE and that the safety profile through five years remained consistent with previously reported data.

Apellis is also advancing a prefilled syringe presentation for SYFOVRE, with a regulatory submission planned in the first half of 2026, and is developing OCT‑F (Optical Coherence Tomography – Functional), an AI imaging tool designed to visualize functional decline and quantify treatment impact in GA for research use in retina specialist practices. In addition, a Phase 2 study of SYFOVRE plus APL‑3007, described as a potential next generation treatment aimed at comprehensively blocking complement activity in the retina and choroid, is ongoing.

Rare disease franchise: kidney and blood disorders

Systemic pegcetacoplan, marketed as EMPAVELI in the United States and Aspaveli in certain ex‑U.S. markets, anchors Apellis’ rare disease franchise. The company highlights several key areas:

• C3G and primary IC‑MPGN – EMPAVELI is the first FDA‑approved treatment for these severe and rare kidney diseases in patients 12 and older. Approval was based on the Phase 3 VALIANT study, which demonstrated a statistically significant 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits compared to placebo. One‑year data from VALIANT showed sustained proteinuria reduction, complete proteinuria remission in a subset of patients, and continued stabilization of kidney function, with a safety profile consistent with prior experience.
• Paroxysmal nocturnal hemoglobinuria (PNH) – EMPAVELI/Aspaveli is approved for adults with PNH in the United States, European Union, and other countries. Apellis reports high patient compliance rates in this indication.
• Additional nephrology indications – Apellis has initiated pivotal trials of EMPAVELI in focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF), two rare kidney diseases characterized by significant complement pathway involvement and high unmet need.

Through these programs, Apellis positions EMPAVELI as a C3 inhibitor with potential across multiple rare complement‑mediated diseases.

Pipeline and research

Beyond its approved therapies, Apellis is advancing an innovative pipeline that leverages its complement expertise. The company reports pre‑clinical research on APL‑90993, described as a potential one‑time neonatal Fc receptor (FcRn) treatment using base editing technology from Beam Therapeutics, with an investigational new drug (IND) submission planned. It also continues to develop combination and next‑generation approaches in ophthalmology, such as SYFOVRE plus APL‑3007, and tools like OCT‑F to better characterize disease and treatment impact.

Collaboration with Sobi

Apellis has a significant collaboration with Swedish Orphan Biovitrum AB (Sobi) related to systemic pegcetacoplan. Under this collaboration, Apellis and Sobi have global co‑development rights for systemic pegcetacoplan. Sobi has exclusive ex‑U.S. commercialization rights for systemic pegcetacoplan, while Apellis retains exclusive U.S. commercialization rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, including for GA.

In a Royalty Buy‑Down Agreement disclosed in a Form 8‑K, Sobi agreed to pay Apellis an upfront payment and potential milestones in exchange for a substantial reduction in Sobi’s ex‑U.S. royalty payment obligations on Aspaveli, subject to defined performance‑based caps. After those caps are reached, Sobi’s royalty obligations revert to the original levels under the collaboration agreement. This structure reflects Apellis’ approach to funding its business and pipeline while maintaining key commercial rights.

Financial profile and commercial stage

Apellis describes itself as a commercial-stage biopharmaceutical company with growing product revenues from SYFOVRE and EMPAVELI. Company disclosures report U.S. net product revenues from both products and note that SYFOVRE has become a significant contributor in GA, while EMPAVELI is building in C3G, primary IC‑MPGN, and PNH. Apellis has also reported substantial cash and cash equivalents and has indicated that it expects its cash, combined with product revenues, to fund operations to profitability.

These financial and commercial details underscore that Apellis is operating with marketed products, active launches in new indications, and ongoing investment in research and development.

Regulatory and safety considerations

Because its medicines modulate the complement system and are used in serious diseases, Apellis’ products carry important safety information. SYFOVRE’s U.S. prescribing information includes contraindications in patients with ocular or periocular infections, active intraocular inflammation, and hypersensitivity to pegcetacoplan or its excipients, as well as warnings and precautions related to endophthalmitis, retinal detachments, retinal vasculitis and/or retinal vascular occlusion, neovascular age‑related macular degeneration, intraocular inflammation, and increased intraocular pressure.

EMPAVELI’s U.S. prescribing information includes a boxed warning for serious infections caused by encapsulated bacteria, reflecting increased susceptibility to infections such as those caused by Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B. Vaccination against encapsulated bacteria and enrollment in the EMPAVELI REMS program are required, and prescribers must follow specific risk management steps. The product information also notes infusion‑related reactions and other adverse reactions observed in clinical studies.

Position within the biopharmaceutical industry

Within the broader pharmaceutical preparation manufacturing industry, Apellis differentiates itself through its concentrated focus on the C3 node of the complement cascade and its portfolio of therapies addressing GA, C3G, primary IC‑MPGN, and PNH. The company repeatedly emphasizes that it has only begun to unlock the potential of targeting C3 across serious diseases, indicating an intention to continue expanding its applications of complement science.

For investors and observers analyzing APLS stock, key aspects include Apellis’ complement‑based scientific platform, its approved therapies SYFOVRE and EMPAVELI/Aspaveli, its collaboration with Sobi, and its ongoing clinical and pre‑clinical programs in ophthalmology and rare kidney diseases.